ArticleFrontiers in endocrinology2025
Case Report: Integrated traditional Chinese and Western medicine in the outpatient management of diabetic foot gangrene complicating uremia.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolism, senescence, and natural products: new perspectives on wound healing in diabetes.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic foot gangrene (DFG) in uremic patients presents profound management challenges due to immune dysfunction and impaired tissue repair. We report on a 65-year-old male patient with end-stage renal disease undergoing peritoneal dialysis, presenting with progressive right foot gangrene that was unresponsive to conventional treatment. Clinical evaluation indicated extensive gangrene affecting the first and second toes, elevated inflammatory markers (C-reactive protein at 95.57 mg/L and fibrinogen at 8.18 g/L), and cardiovascular compromise (brain natriuretic peptide at 4869 pg/mL). Lower limb computed tomography angiography confirmed severe atherosclerosis. An integrated protocol combining Yanghe Sijunzi Decoction with meticulous debridement and localized analgesia was implemented over 7 months (18 outpatient visits). This approach resulted in complete ulcer healing by October 2024, with the resolution of gangrene, an 87% reduction in CRP levels (to 12 mg/L), normalization of coagulation markers, and preservation of foot function-thus preventing amputation. Patient-reported outcomes, including pain scores and sleep duration gradually improved as healing advanced from 23 March 2024. The total treatment costs amounted to 25,000 CNY, with the patient's share being 5,000 CNY, demonstrating cost-efficiency. This case highlights Traditional Chinese Medicine's potential as an immunomodulatory adjuvant in uremia-associated DFG, modulating inflammation and promoting tissue regeneration in high-risk patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.